FDA hopes to have revised guidance on in vivo bioequivalence studies for conjugated estrogens out by the end of the year. Draft was issued on June 16 ("The Pink Sheet" June 26, p. 5). However, FDA said issuance of revised guidance may be delayed if the agency decides document should be reviewed by Fertility and Maternal Health Drugs Advisory Committee, which is next scheduled to meet Feb. 1-2. Guidance was discussed at Oct. 20 meeting between FDA and Able Labs. Able said it is doing groundwork for in vivo bioequivalence studies and that FDA advised it to wait for the guidance before proceeding further. FDA previously had rejected Able's urinary excretion-based ANDA for estrogens.
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.